Biopharmaceuticals

Chino, Calif. – September 13, 2026 -- Specialty Enzymes & Probiotics has published dual-track research showing its ingredient SlimSEBTM reduces post-meal blood sugar spikes by 16.90% in a controlled human clinical trial, providing formulators with clinically backed data for glucose-support supplements.

Clinical trial confirms 16.90% reduction in glucose AUC

In a double-blind, randomized, placebo-controlled crossover trial, subjects supplemented with SlimSEBTM showed a 16.90% reduction in Area Under the Curve (AUC), a standard measure of post-prandial glycemic response. The result demonstrates statistically significant improvement in blood sugar control following meals.

Cambridge, Mass. – September 13, 2026 -- Solstice Oncology has launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors, to advance a second-generation CTLA-4 antibody into earlier-stage cancer treatment.

Solstice secures $225 million to fund neoadjuvant immuno-oncology program

The clinical-stage company is focused on treating cancer in the neoadjuvant setting, before tumors have hardened resistance to therapy. Its lead candidate, porustobart, is a differentiated, Fc-enhanced CTLA-4 antibody being developed across two clinical indications, including microsatellite-stable (MSS) colon cancer and a second, undisclosed indication.

Los Angeles – September 13, 2026 -- Partillion Bioscience has secured a two-year, $2.1 million NIH Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences (NIGMS), pushing the company's total non-dilutive federal funding past $8 million.

Tenth SBIR grant matches private capital raised to date

The award, Partillion's 10th SBIR grant, was competitively secured through NIH's Direct-to-Phase II mechanism and roughly matches the company's private investment total, with no additional equity exchanged. The funding, awarded under grant number R44GM165220, will support development of the company's Cell-Cell-seq workflows over two years.

Toronto – September 13, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will hold a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT.

Cardiol schedules investor session at Lotte New York Palace Hotel

The session takes place in the Louis Room on the fourth floor of the venue. A live webcast will be available under the Events & Presentations section of the company's investor website.

Company advances Phase III trial for recurrent pericarditis treatment

Cardiol's lead candidate, CardiolRx, is being evaluated in the pivotal Phase III MAVERIC trial (NCT06708299) for recurrent pericarditis, following the completed Phase II MAvERIC-Pilot study (NCT05494788). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for pericarditis, including the recurrent form of the disease.

Sydney – September 13, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has dosed the first patient in Arm A of PNOC035, a Phase 2 platform study testing paxalisib combined with gemcitabine for recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT), an aggressive pediatric brain cancer with no approved therapies.

Preclinical data showed the combination nearly quadrupled median survival in an AT/RT model

In an orthotopic AT/RT preclinical model, the paxalisib-gemcitabine combination extended median survival from 22 to 82.5 days (p0.0001) and showed complementary anti-tumor activity across multiple AT/RT cell lines. These findings, previously presented at ISPNO, AACR and Neuro-Oncology meetings, formed the scientific basis for advancing into the multicenter PNOC035 trial.

Ramat Gan, Israel – September 13, 2026 -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) will rebrand as Eocene Ltd. and begin trading under the ticker EOCN on the Nasdaq Capital Market starting September 10, 2026, after terminating its $20 million standby equity purchase agreement with Yorkville and regaining compliance with Nasdaq's minimum bid price rule.

Company terminates $20 million Yorkville equity facility after raising $7.3 million

Galmed terminated its Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville), effective September 8, 2026. The facility had provided up to $20 million in equity financing; the company raised approximately $7.3 million through the issuance of 437,947 ordinary shares before termination.

College Station, Texas – September 13, 2026 -- Matica Biotechnology, a Texas-based cell and gene therapy CDMO, has entered a collaboration with Bondwell Technologies to advance the latter's proprietary protein bioprocessing platform toward manufacturing readiness.

Matica Bio will provide development expertise to prepare Bondwell's technology for commercialization

Under the agreement, Matica Bio will support Bondwell Technologies, headquartered in College Station, in scaling its proprietary protein technology for bioprocessing and life science applications. The collaboration is designed to move Bondwell's platform closer to manufacturing readiness and future commercial deployment.

Cambridge, Mass. – September 13, 2026 -- Marengo Therapeutics has completed enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001 trial evaluating invikafusp alfa across eight distinct PD-1-resistant tumor types, with updated results selected for an oral presentation at the ESMO 2026 Congress in Madrid, October 23-27.

Trial enrollment closes across eight PD-1-resistant tumor types

The monotherapy cohorts covered patients with MSS colorectal cancer, PD-L1-negative non-small cell lung cancer and triple-negative breast cancer, among others resistant to checkpoint blockade. Enrollment continues in standard-of-care combination cohorts, while the company plans to name lead indications for focused development alongside the ESMO data release.

Dallas – September 13, 2026 -- The U.S. Food and Drug Administration has accepted and filed the Biologics License Application for MOGENRY, an optogenetic gene therapy from Nanoscope Therapeutics designed to restore vision in retinitis pigmentosa patients with severe vision loss. If approved, MOGENRY would become the first gene-agnostic treatment available for this patient population, which currently has no approved therapy.

RESTORE trial data anchors the regulatory filing

The BLA is supported by the Phase 2b/3 RESTORE trial (NCT04945772), a multicenter, randomized, double-masked, sham-controlled study that met its primary and key secondary endpoints, showing improvements in visual acuity at weeks 52 and 76. No treatment-related serious adverse events were reported. Additional efficacy and safety data come from the earlier Phase 1/2a trial (NCT04919473).

Wellesley Hills, Mass. – – September 13, 2026 -- Cure Alzheimer's Fund (CureAlz) has appointed Drs. Michelle Arkin, Ronald B. DeMattos, Donna M. Huryn, and Kalpana Merchant to its Scientific Advisory Board (SAB), adding decades of pharmaceutical drug-discovery experience to the nonprofit's research-funding strategy.

Board addition brings direct experience from an FDA-cleared Alzheimer's drug

Ronald B. DeMattos spent more than 20 years in neuroscience discovery at Eli Lilly, most recently as Senior Vice President and Chief Scientific Officer for Neurobiologics, where he led development of candidates that advanced to clinical studies including donanemab, the FDA-cleared amyloid-lowering antibody marketed as Kisunla for early Alzheimer's disease.